New drug - Ecalta

Pfizer has launched Ecalta (anidulafungin) for the treatment of invasive candidiasis in adult non-neutropenic patients.

Anidulafungin is an antimycotic agent with fungicidal activity against Candida species and activity against regions of active cell growth of the hyphae of Aspergillus fumigatus. It exerts its effect through selective inhibition of 1,3-beta-D glucan synthase, an enzyme present in fungal but not mammalian cells, thereby inhibiting the formation of 1,3-beta-D glucan, an essential component of the fungal cell wall.


Anidulafungin was evaluated in a double-blind, non-inferiority study1 comparing it with fluconazole for the treatment of candidaemia and other forms of invasive candidiasis in patients aged 16 years and over (n=245).

Patients were randomised to intravenous anidulafungin (200mg on day one then 100mg daily, n=127) or intravenous fluconazole (800mg on day one then 400mg daily, n=118).

The primary endpoint was global success at the end of intravenous therapy, defined as both clinical success (resolution of signs and symptoms of invasive candidiasis and no need for additional systemic antifungal therapy) and microbiological success (eradication of Candida species present at baseline, as determined on follow-up culture, or the presumed eradication if culture data not available for a patient with a successful clinical response).

Overall, a successful response was achieved in 75.6 per cent of patients in the anidulafungin group compared with 60.2 per cent of those in the fluconazole group.

In patients with candidaemia only, 75.9 per cent in the anidulafungin group and 61.2 per cent in the fluconazole group achieved a successful response. Similarly, among patients with other forms of invasive candidiasis a greater proportion of patients in the anidulafungin group achieved a successful response than in the fluconazole group.

1. Reboli A, Rotstein C, Pappas P et al. Anidulafungin versus fluconazole for invasive candidiasis. N Engl J Med 2007: 356: 2472–82.


Further information: Pfizer 01304 616161

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Already registered?
Sign in

More from MIMS

Women taking valproate still unaware of pregnancy risks, survey finds

Women taking valproate still unaware of pregnancy risks, survey finds

One in ten women currently taking valproate are unaware...

Live updates: Coronavirus (COVID-19) in the UK

Live updates: Coronavirus (COVID-19) in the UK

Use our timeline to follow the latest coronavirus developments...

Experts urge vitamin D supplementation and call for research into possible COVID-19 benefits
Drug shortages - live tracker

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...